Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) plus platinum-based chemotherapy (PBC) vs placebo (PBO) plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)


Bamias A., De Santis M., Arranz J. A. , Grande E., Galsky M. D. , Kikuchi E., ...More

ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31 identifier